Search

Copyright of Journal of Behcet Uz Children's Hospital is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Behcet Uz Children's Hospital is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Pediatric Infection / Çocuk Enfeksiyon Dergisi is the property of Journal of Pediatric Infection / Cocuk Enfeksiyon Dergisi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Chickenpox, the primary infection of the Varicella-zoster virus (VZV), is usually a benign, self-limiting disease and it rarely causes severe complications. Encephalitis is a rare neurological complication of VZV in previously healthy children. We report on an immunocompetent child without vaccination diagnosed with VZV encephalitis who was treated with acyclovir and methylprednisolone and recovered completely. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Pediatric Infection / Çocuk Enfeksiyon Dergisi is the property of Journal of Pediatric Infection / Cocuk Enfeksiyon Dergisi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of ANKEM Antibiyotik & Kemoterapi Dergisi is the property of ANKEM Antibiyotik & Kemoterapi Dergisi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Pediatric Infection / Çocuk Enfeksiyon Dergisi is the property of Journal of Pediatric Infection / Cocuk Enfeksiyon Dergisi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVES: Coronavirus disease 2019 (COVID-19) that causes a respiratory illness, continues to be a global pandemic. In this study, we purpose to identify the features of children with COVID-19 and the factors affecting disease severity. METHODS: This is a retrospective, observational study was conducted on patients who presented with suspicion of COVID-19 from April 1, 2020, to March 31, 2021, at a tertiary care medical center in Turkey. The characteristics of 640 children who were confirmed to have COVID-19 by real-time reverse transcription-polymerase chain reaction were retrieved from medical records. RESULTS: The mean age of the cases was 10 ± 6 years, and 56% of them were male. Seasonal difference did not affect the number of cases. The majority of the cases (n = 501, 78%) were infected by family members. Fever (67%) and cough (38%) were common complaints. The mean duration of fever was 1.9 ± 1.1 days. One-fourth of the cases were asymptomatic, 462 (72%) had mild upper respiratory tract infections, and 18 (3%) had pneumonia. Patients with pneumonia were more likely to have comorbidities and had a longer fever duration (both P < 0.001). Fever, cough, and respiratory distress were more common in patients with pneumonia (P = 0.010, P = 0.023, and P < 0.001, respectively). The mean C-reactive protein (CRP) value of the patients with pneumonia was significantly higher than that of the others (P < 0.001). A total of 70 (11%) complicated patients were hospitalized, 5 of them requiring intensive care admission. All hospitalized patients were discharged with recovery. CONCLUSIONS: Although pediatric COVID-19 patients tended to have a mild disease, some children with comorbidities can still develop a severe illness. CRP value is a useful indicator in the diagnosis of COVID-19 pneumonia. Furthermore, the prevalence rate of COVID-19 did not decrease with hot seasons. [ABSTRACT FROM AUTHOR]

This document is a response to a letter titled "Rehospitalization indications of children hospitalized for COVID-19 infections and long COVID." The authors of the response express gratitude for the interest in their research and provide additional information regarding their study. They conducted the research in a tertiary care children's hospital and included 777 patients, 98 of whom were rehospitalized. The reasons for rehospitalization varied, with some patients being rehospitalized due to their underlying disease or unrelated infections, while others presented with ongoing symptoms following SARS-CoV-2 infection. The study did not account for confounding factors and limitations were acknowledged. Ethical approval was obtained, and the authors declare no conflict of interest. [Extracted from the article]

Copyright of Journal of Pediatric Infection / Çocuk Enfeksiyon Dergisi is the property of Journal of Pediatric Infection / Cocuk Enfeksiyon Dergisi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Amaç: İnvazif fungal enfeksiyonlar, sınırlı tedavi seçenekleri nedeniyle hastanede yatan ve bağışıklığı baskılanmış çocuk hastalarda önemli bir mortalite ve morbidite nedenidir. Mikafungin, çocuk hastalarda invazif fungal enfeksiyonların tedavisi için en yeni onaylanmış ekinokandin grubu bir antifungaldir; ancak, çocuklarda etkililik ve yan etkileri hakkındaki veriler sınırlıdır. Bu çalışmada, mikafungin tedavisi veya profilaksisi kullanan çocuk hastaların özelliklerinin, tedaviye yanıtlarının ve yan etki sıklığının değerlendirilmesi amaçlanmıştır. Gereç ve Yöntem: Tek merkezde, Ocak 2017-Aralık 2019 tarihleri arasında tedavi veya profilaksi için mikafungin kullanan <18 yaş çocuk hastalar geriye dönük olarak değerlendirildi. Bulgular: Çalışmamızda profilaksi için mikafungin kullanan 52 hasta ve tedavi için mikafungin kullanan 39 hastanın 43 epizodu değerlendirildi. Tedavi için mikafungin kullanan hastaların yaş ortalaması 5,93±6,1 yıl ve profilaksi için mikafungin kullanan hastaların yaş ortalaması 5,54±5,0 yıl idi. Mikafungin tedavisi, 18 (%41,9) hastada etkene yönelik tedavi, 15 (%34,9) hastada ampirik tedavi ve 10 (%23,3) hastada febril nötropeni için kullanıldı. Hastaların tedavi için mikafungin kullanma süresi ortalama 16,9±10,8 gün idi. Tedavi etkinliği değerlendirildiğinde hastaların %79,1'inde klinik yanıt, %81,3'ünde mikolojik yanıt alındı. Tedavi için mikafungin kullanan hastalarda hepatik yan etki %20,9 oranında ve renal yan etki %2,3 oranında görüldü. Tedavide mikafungin kullanan hastalarda 14 günlük ve 30 günlük mortalite oranı sırasıyla %7 ve %9,3 idi. Mikafungin profilaksisi kullanan hastalarda profilaksi süresi 42 (%80,8) hastada <=1 ay ve 10 (%19,2) hastada >1 aydı. Profilaksi için mikafungin kullanan 3 (%5,8) hastada breakthrough invaziv fungal enfeksiyon gelişti (1 kanıtlanmış, 1 olası, 1 şüpheli). Profilaksi için mikafungin kullanan hastalarda hepatik yan etki %13,5 oranında ve renal yan etki %5,8 oranında görüldü. Profilaksi için mikafungin alan hastalarda 14 günlük ve 30 günlük mortalite oranı sırasıyla %0 ve %1,8 idi. Ancak, mikafungin kullanan hastalarda görülen ölümler hem profilaksi hem de tedavi gruplarında mantar enfeksiyonu ile ilişkili değildi. Sonuç: Bulgularımız, mikafunginin pediyatrik hastalarda invaziv fungal enfeksiyonların tedavisi veya profilaksisi için kullanıldığında güvenli ve etkili bir antifungal ajan olabileceğini düşündürmüştür. Çocuklarda mikafungin kullanımının etkinliğini ve güvenliğini değerlendirmek için daha fazla ve daha geniş prospektif çalışmalara ihtiyaç vardır. [ABSTRACT FROM AUTHOR]

Copyright of Mediterranean Journal of Infection, Microbes & Antimicrobials is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)